Canaquest Store

CanaQuest Medical (CANQF), a clinical-stage, life sciences company, is focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and PPAR receptors. The Company is prioritizing treating neurological conditions such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD," including addiction. CanaQuest has three divisions, pharmaceutical, nutraceutical, and veterinary. The Company has partnered with world-leading organizations in research, manufacturing, and commercialization with expertise in neuroscience, psychiatry, veterinary, and professional sports. Breakthrough Discovery: cannabidiol “CBD” + essential fatty acids, Pre-clinical Trials conducted by Dr. Steven Laviolette, Western University, Demonstrated amplified effects and efficacy. Clinical Studies on mouse models for epilepsy completed at the Ontario Brain Institute, Demonstrated 50% more seizure reduction. US-FDA & Health Canada - New Drug Application “NDA” submission for Phase clinical trials, Drug Identification Number “DIN” approval is projected ∼ 3 years & ∼ 2 years, respectively. Partnerships: Neeka Health, the NHLAA, and Dr. Paul Dick, Paul Dick & Associates, the veterinary division, Dr. Hunter Land, CSO of Neeka, co-led the clinical development of Epidiolex® (FDA-approved DIN) for GW Pharma and will lead all trials/studies. Nutraceutical: Mentanine®, an OTC version of CQ-001, is available via CanaQuest Store, in the US. Produced for Clinical (human) Studies to obtain Data for various indications, and future Clinical Trials. Exit Strategy: IPO, large pharma buyout. GW Pharma was bought by Jazz Pharma ($7.2 B), Pfizer signed an agreement ($6.7 B) with clinical-stage Arena Pharma, betting on a promising cannabinoid-based bowel disease treatment, CAGR, the global market, for medical cannabis is estimated at 24% over four years, which could considerably rise if federal laws loosen.